Rhamnose Binding Protein as an Anti-Bacterial Agent-Targeting Biofilm of Pseudomonas aeruginosa by Fu, Tse-Kai et al.
marine drugs 
Article
Rhamnose Binding Protein as an Anti-Bacterial
Agent—Targeting Biofilm of Pseudomonas aeruginosa
Tse-Kai Fu 1,2, Sim-Kun Ng 1, Yi-En Chen 1, Yuan-Chuan Lee 1,3, Fruzsina Demeter 4,
Mihály Herczeg 4 , Anikó Borbás 4, Cheng-Hsun Chiu 5, Chung-Yu Lan 1,5 , Chyi-Liang Chen 6
and Margaret Dah-Tsyr Chang 1,5,*
1 Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan;
gn00042366@gmail.com (T.-K.F.); flyingsim02@hotmail.com (S.-K.N.); ian8004@gmail.com (Y.-E.C.);
yclee@jhu.edu (Y.-C.L.); cylan@life.nthu.edu.tw (C.-Y.L.)
2 Simpson Biotech Co., Ltd., Taoyuan 333, Taiwan
3 Department of Biology, Johns Hopkins University, Baltimore, ML 21218, USA
4 Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen 4032, Hungary
demeter.fruzsina@science.unideb.hu (F.D.); herczeg.mihaly@science.unideb.hu (M.H.);
borbas.aniko@pharm.unideb.hu (A.B.)
5 Department of Life Science, National Tsing Hua University, Hsinchu 30013, Taiwan;
chchiu@adm.cgmh.org.tw
6 Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Chang Gung University
College of Medicine, Taoyuan 333, Taiwan; dinoschen@adm.cgmh.org.tw
* Correspondence: dtchang@life.nthu.edu.tw; Tel.: +886-3-574-2767
Received: 24 May 2019; Accepted: 12 June 2019; Published: 14 June 2019


Abstract: More than 80% of infectious bacteria form biofilm, which is a bacterial cell community
surrounded by secreted polysaccharides, proteins and glycolipids. Such bacterial superstructure
increases resistance to antimicrobials and host defenses. Thus, to control these biofilm-forming
pathogenic bacteria requires antimicrobial agents with novel mechanisms or properties. Pseudomonas
aeruginosa, a Gram-negative opportunistic nosocomial pathogen, is a model strain to study biofilm
development and correlation between biofilm formation and infection. In this study, a recombinant
hemolymph plasma lectin (rHPLOE) cloned from Taiwanese Tachypleus tridentatus was expressed in
an Escherichia coli system. This rHPLOE was shown to have the following properties: (1) Binding to
P. aeruginosa PA14 biofilm through a unique molecular interaction with rhamnose-containing moieties
on bacteria, leading to reduction of extracellular di-rhamnolipid (a biofilm regulator); (2) decreasing
downstream quorum sensing factors, and inhibiting biofilm formation; (3) dispersing the mature
biofilm of P. aeruginosa PA14 to improve the efficacies of antibiotics; (4) reducing P. aeruginosa PA14
cytotoxicity to human lung epithelial cells in vitro and (5) inhibiting P. aeruginosa PA14 infection
of zebrafish embryos in vivo. Taken together, rHPLOE serves as an anti-biofilm agent with a novel
mechanism of recognizing rhamnose moieties in lipopolysaccharides, di-rhamnolipid and structural
polysaccharides (Psl) in biofilms. Thus rHPLOE links glycan-recognition to novel anti-biofilm
strategies against pathogenic bacteria.
Keywords: rhamnose-binding protein; anti-biofilm; quorum sensing factor; anti-infection
1. Introduction
Part of the reasons for bacterial resistance to antibiotics are due to the formation of biofilm,
composed of secreted polysaccharides, proteins, glycolipids and small molecules in the bacterial
microenvironment. Recent development of antimicrobial agents with novel molecular mechanisms to
control bacterial infectious diseases has drawn much attention [1]. The inhibition of bacterial biofilm
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formation by non-microbicidal mechanisms is an example of anti-pathogenic approaches [2,3]. One
nosocomial infectious bacteria, Pseudomonas aeruginosa, is responsible for various infections, particularly
in immuno-compromised individuals [4], and it forms biofilms to make antibiotic treatments inefficient
and therefore promotes acute infections, for example, at upper airway, skin, wound, urinary tract,
enteric and lung [5]. P. aeruginosa PA14 is a clinically isolated and highly virulent strain representing the
most common clonal group worldwide [6]. The PA14 genome showing a high degree of conservation
compared to that of the P. aeruginosa strain PAO1 contains two specific pathogenicity islands. The PA14
islands carried several genes implicated in virulence that are absent in PAO1, including genes encoding
effectors of the type III secretion system for secreting virulent factors [7,8]. These characteristics make
PA14 a threat to public health, but a good model for P. aeruginosa infection studies.
Biofilm development is associated with changes in bacteria phenotype and metabolic pathways [9].
During biofilm development, physiological changes of bacterial cells are regulated by a chemical
signaling mechanism involving cell-to-cell communication, such as quorum-sensing (QS) signaling.
The process of P. aeruginosa biofilm development is mainly regulated by three interconnected QS
systems: Two use acyl-l-homoserine lactones (AHLs) and the third uses aquinolone [10]. In the
AHL QS system, LasI-synthase generates N-(3-oxododecanoyl)-l-homoserine lactone [11] and RhlI
synthase generates N-butyryl-l-homoserine lactone [12]. The former is a key factor in the maturation
stage of the biofilm [13], and the latter is responsible for production of another biofilm regulator,
di-rhamnolipid [14]. Numerous molecules with anti-QS property have been reported to inhibit biofilm
formation of P. aeruginosa [15]. AHL analogues have inhibitory activities on biofilm formation in
P. aeruginosa by down-regulating LasR-based QS system (LasR, a transcriptional regulator response
for AHL). Some modified AHL analogues can also down-regulate pyocyanin, a virulence factor with
elastase activity [16]. Certain enzymes are secreted by mammalian cells such as paraoxonases, which
lactonase activity can degrade P. aeruginosa AHLs and further inhibit QS and biofilm formation. Most
of these AHL pathway inhibitors efficiently work under 10 µM.
There already exist many different anti-biofilm agents from various resources. For example,
cultured broth from certain marine cold adapted bacteria destabilized biofilm of Pseudomonas
aeruginosa [17] and some essential oils from Mediterranean plants or selected exopolysaccharide from
marine bacteria acts as anti-QS factors to inhibit biofilm formation of Pseudomonas aeruginosa [18,19].
Although AHL pathway inhibitors already exist, they still cannot completely inhibit the biofilm
produced by P. aeruginosa [15], indicating that biofilm development is not only controlled by the AHL
pathway but also other pathways that might partially complement to develop biofilm. This hypothesis
leads us to focus on factors that may directly regulate biofilm development. Di-rhamnolipid, as a
glycolipid secreted by P. aeruginosa, has been implicated in each of the following phases of biofilm
development: (i) Forming microcolonies [20], (ii) regulating both cell-to-cell and cell-to-surface
interactions [21], (iii) creating and maintaining fluid channels for water and oxygen flow around the
base of the biofilm [21] and (iv) facilitating 3-D mushroom-shaped structure formation [22]. Accordingly,
di-rhamnolipid seems to be a regulator that might directly interact with biofilms. The influence of
di-rhamnolipid to biofilm development was observed, but the interaction of di-rhamnolipid with other
QS factors remains unclear. To develop anti-biofilm reagents directly targeting di-rhamnolipid might
be a novel anti-biofilm approach.
Rhamnose binding proteins (RBPs) are mainly isolated from eggs, ovary cells of fish and
invertebrates with l-rhamnose (Rha) or d-galactose binding specificities [23,24]. RBPs are typically
located in immune-related tissues or cells [25], suggesting that RBPs may be relevant to self-defense
mechanisms. RBPs may interact and agglutinate Gram-negative and Gram-positive bacteria by
recognizing lipopolysaccharide (LPS) and lipoteichoic acid (LTA), respectively [26]. RBPs can recognize
some O-antigens and bind to glycolipids and glycoproteins of fish pathogens [27]. The RBP receptor
is expressed on peritoneal macrophages of fish after an inflammatory stimulation [28]. The tissue
specificity of expression and ability to interact with bacteria indicates that RBPs are naturally related to
the innate immune system in animals as a pathogen recognition element.
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An RBP possessing specific binding of l-rhamnose was discovered from horseshoe crab plasma
and recently engineered for expression in the Escherichia coli system [29]. This recombinant horseshoe
crab plasma lectin (rHPL) possesses a very low sequence identity with known RBPs and does not have
conserved domains. Interestingly, rHPL binds to bacteria or pathogen-associated molecular patterns
(PAMPs) by recognizing rhamnose moieties and inhibits the growth of P. aeruginosa [29]. Unlike other
RBLs, rHPL only binds to l-rhamnose and rhamnobiose but not to galactose or mannose [30]. This high
substrate specificity makes rHPL a prospective candidate to bind rhamnose-containing components in
biofilm of P. aeruginosa and examine the biological functions of these bindings.
2. Results
2.1. rHPLOE Was Expressed in E. coli and Purified by Affinity Chromatography
rHPL was successfully expressed in E. coli in 2014. The yield of rHPL purified using a nickel-affinity
column was ~8 mg/L, and the purity was 93% [29]. To improve the productivity and solubility of
rHPL, the codon usage of synthetic hpl (hploe) was optimized for E. coli, and recombinant HPLOE
was co-expressed with chaperones. The expression product, rHPLOE, was purified by fast protein
liquid chromatography (FPLC) equipped with a HisTrap™ affinity column following purification
scheme in supplementary data showed in Table S1. rHPLDM, representing rHPL with two artificial
mutations Y88A and F145A, which showed no binding activities to a bacterial cell- (Figure S1A)
or pathogen-associated molecular pattern (PAMP; Figure S1B), was applied as a negative control
in this study. Figure S2 illustrated the purification chromatogram and SDS polyacrylamide gel
electrophoresis analysis data. The purified rHPLOE was desalted and concentrated using an Amicon
protein concentrator (10 kDa cut-off) and subjected to further analysis. Figure S3 showed the secondary
structure of rHPLOE determined by circular dichroism (CD) spectroscopy in comparison to those of
rHPL and rHPLDM, indicating that both rHPLOE and rHPLDM possessed similar structures to rHPL [29].
A yield of 11.33 mg/L rHPLOE with a comparable purity. The yield of rHPLOE was 1.4-fold higher than
that of rHPL, suggesting that the chaperone improved the solubility and stability of rHPL in the E.
coli system.
2.2. rHPLOE Bound to Cell-Free Biofilm Matrix from P. aeruginosa PA14 via Recognizing Rhamnose
Our hypothesis is that rHPLOE might bind to rhamnose-containing components in the biofilm
and further interrupt bacterial biofilm development. First, binding capacity of rHPLOE to the cell-free
biofilm matrix from P. aeruginosa PA14 was tested. Here, a mature P. aeruginosa PA14 biofilm was
extracted using a NaCl solution to give a cell-free biofilm matrix. In the extracted PA14 biofilm,
the total protein was 0.19 mg/mL and polysaccharide, 0.32 mg/mL. Di-rhamnolipid, an important
QS-factor and putative binding target of rHPLOE, was extracted using chloroform, and was 0.66 µg/mL
by methylene blue method. The interaction between rHPLOE and the cell-free biofilm matrix was
measured by ELISA, and the inhibitory effect of monosaccharides and alginate on rHPLOE-biofilm
interaction was determined using competitive ELISA. rHPLOE at a final concentration of 0.1 µM was
mixed with l-rhamnose and loaded into microplate wells coated separately with extracted P. aeruginosa
PA14 biofilm. rHPLOE mixed with buffer only was used as a positive control. rHPLDM without
rhamnose binding activity served as a negative control. As shown in Figure 1, addition of 25, 50, and
100 mM of l-rhamnose effectively reduced binding of rHPLOE to the extracted biofilm, in comparison
with the positive control. The inhibitory constant (Ki) of l-rhamnose to rHPLOE interaction with the
biofilm of P. aeruginosa PA14 was 98 mM. The addition of 100 Mm of d-mannose, d-glucose, d-fructose,
d-galactose and alginate could not reduce the binding between rHPLOE and the extracted biofilm. These
results indicated that rHPLOE specifically bound to rhamnose containing components in P. aeruginosa
PA14 biofilm.
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Figure 1. Inhibitory effects of monosaccharides on the recombinant hemolymph plasma lectin
(rHPLOE)-biofilm interaction. The binding activity of rHPLOE to the PA14 biofilm and inhibitory effects
of monosaccharides or alginate on this binding were determined by competitive ELISA. rHPLDM was
applied as a negative control. *** p < 0.001 versus the rHPLOE only group (positive control).
2.3. Synthetic Rhamnobiosides and a Pentasaccharide Inhibited rHPLOE-Biofilm Interaction
To confirm that binding of rHPLOE to the P. aeruginosa PA14 biofilm was via molecular recognition
of rhamn se moiety, synthetic rhamno-oligosaccharides (Figure 2A,B) were used as competitors in a
competitive ELISA. The chemical synthesis of phenylthio-rhamnobiosides and the Psl-pentasaccharide
will be published elsewher . The characterization of the new oligosacc arides used in thi study is
given in the Suppl mentary Information (Figures S4–S6).
Figure 2 indicated that all synthetic compou ds competed with the rHPLOE-biofilm interaction.
The disaccharides are better inhibitor than monosaccharides, and (1-3)-linked rhamnosides were better
than its (1-2)-linked counterparts. Psl-pentasaccharide showed the strongest competition presumably
due to longer glycan chain length. The competitive effects of rhamnobiosides were stronger than those
of rhamnobioses, indicating either a fixed anomeric configuration or hydrophobicity of aglycones
slightly favors binding.
2.4. rHPLOE Bound to Di-Rhamnolipid via Recognizing Rhamnose Portion
After confirming the binding activity of rHPLOE to synthetic rhamnobiosides, direct binding
activity of rHPLOE to di-rhamnolipid from P. aeruginosa PA14 biofilm was measured by ELISA.
Further competitive ELISA indicated that rHPLOE binding to di-rhamnolipid could be competed more
effectively by l-rhamnose compared to other monosaccharides (Figure 3).
2.5. rHPLOE Inhibited Biofilm Formation and Dispersed the Preformed Biofilm of P. aeruginosa PA14
This experiment was conducted in M63 broth, a minimal low-osmolarity medium to slow down
the growth rate of bacteria and mimic nutrient-depleted conditions for biofilm growth [31]. rHPLDM
was applied as a negative control. As shown in Figure 4A, 0.31 µM and higher concentrations up to 5
µM of rHPLOE significantly inhibited the biofilm formation of P. aeruginosa PA14. Treatment with 0.31,
0.63, 1.25, 2.5 and 5 µM rHPLOE significantly reduced biofilm formation to 49%, 51%, 39%, 18% and
13%, respectively. As expected, rHPLDM did not inhibit biofilm formation. rHPLOE was also evaluated
for its biofilm dispersion activity with preformed biofilm. The mature biofilm of P. aeruginosa PA14 was
dispersed by 16% and 24% upon treatment with 2.5 and 5 µM rHPLOE for 24 h, respectively (Figure 4B).
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However, rHPLDM did not disperse the mature biofilm. These results indicated that rHPLOE inhibited
biofilm formation and dispersed the mature biofilm of P. aeruginosa PA14 and that both activities
perhaps are correlated with the rhamnose binding activity.
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phenylthio-1-2-rhamnobioside, phenylthio-1-3-rhamnobioside, propargyl-1-3-rhamnobioside and 
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Figure 2. Structures of synthesized rhamnobioses and the rhamnose-containing Psl-pentasaccharide
and inhibitory effects of thereof on the rHPLOE-biofilm interaction. (A) Structures of the
synthesized rhamnosyl di- and pentasaccharides: α(1-2)-rhamnobiose, α(1-3)-rhamnobiose,
phenylthio-1-2-rhamnobioside, phenylthio-1-3-rhamnobioside, propargyl-1-3-rhamnobioside and
Psl-pentasaccharid . (B) The binding activity of rHPLOE on the biofilm from Pseudomonas aeruginosa
PA14 and the inhibitory effects of rhamnose or rhamnobiosides on this binding were determined by
competitive ELISA. *** p < 0.001 versus the rHPLOE-only group.
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2.6. rHPLOE Inhibited Swarming Activity and Decreased Secreted Rhamnolipids of P. aeruginosa PA14
Swarming motility is positively correlated with the amount of extracellular rhamnolipids, leading
to rapid bacterial translocation that promotes efficient colonization of bacterial cells on a surface [32].
Under optimal growth conditions, P. aeruginosa cell population would spread along a solid surface and
cover a large area. If swarming were inhibited, the bacterial cell population would gather together to
form a colony. The swarming area of P. aeruginosa PA14 was significantly reduced upon treatment
with rHPLOE but not rHPLDM (Figure S7A). The swarming area of PA14 was reduced by 33%, 43%,
48% and 46%, respectively, upon treatment with 0.63, 1.25, 2.5 and 5 µM rHPLOE for 72 h (Figure S7B).
Figure 5 showed that the extracellular rhamnolipid levels of PA14 (11.7 ± 0.4 µg/mL in the control
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treated with buffer) reduced by 44%, 50%, 54%, 64% and 59% upon treatment with 0.31, 0.63, 1.25, 2.5
and 5 µM rHPLOE, respectively. However, the 5 µM rHPLDM treatment did not affect the extracellular
rhamnolipid levels of PA14. This result was consistent with the swarming assay, indicating that the
binding of rHPLOE to biofilm inhibited PA14 swarming activity by down-regulating the levels of
extracellular di-rhamnolipid.
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or rHPLDM. Extracellular rhamnolipids of P. aeruginosa PA14 treated by rHPLOE or rHPLDM were
measured by the chloroform–methyl blue method. *** p < 0.001 versus the buffer-treated group.
2.7. rHPLOE Attenuated QS-Associated Factors
The development of biofilms appears to be regulated by the QS system. Most reagents that
attenuate biofilm development work through inhibiting production of QS-factors or disrupting
function of QS-factors by direct binding to QS-factors [33–35]. Among these agents, pyoverdine and
pyocyanin are unique toxic molecules related to the virulence of P. aeruginosa PA14. To understand
the attenuation mechanism of P. aeruginosa biofilm by rHPLOE, the effect of rHPLOE on QS-mediated
azocasein-degrading protease activity and the secretion of two virulent factors, pyoverdine and
pyocyanin were evaluated. Bacterial extracellular proteases degrade proteins in host cells (infected
tissue), thereby facilitating bacterial invasion and growth [36]. Interestingly, bacterial protease secretion
by P. aeruginosa PA14 was down-regulated by rHPLOE treatment (Figure S8A). The azocasein-degrading
assay showed that 1.25 and 2.5 µM rHPLOE respectively decreased 16% and 12% of total proteolytic
activities. Treatment with 0.31, 0.63, 1.25 and 2.5 µM rHPLOE decreased the pyoverdine levels by
12%, 8%, 17% and 21%, respectively (Figure S8B). Treatment with the same concentrations of rHPLOE
decreased the pyocyanin levels by 41%, 56%, 45% and 40%, respectively (Figure S8C).
These results indicated that the binding of rHPLOE to the biofilm down-regulated the protease
activities and QS-factors (Table 1). Consistent with previous observations, 2.5 µM rHPLDM did not
show an inhibitory effect. Relatively weak inhibition of rHPLOE on protease activity and pyoverdine
expression indicated that these effects might be indirect effects. The effect of rHPLOE on pyocyanin
production was detectable but not concentration-dependent. A possible alternate reason for this
may be that the inhibition effect of rHPLOE on pyocyanin production was compensated by other
regulatory pathways.
2.8. Combination Treatment with rHPLOE Improved Efficacies of Antibiotics on P. aeruginosa with
Preformed Biofilms
Since rHPLOE exhibited dispersion of P. aeruginosa PA14 biofilm, we hypothesized that rHPLOE
might increase the activities of antibiotics against P. aeruginosa PA14 in mature biofilms. Total protein
assay showed that the combination of rHPLOE with either azithromycin (hydrophobic) or cephalexin
(hydrophilic) significantly attenuated the total protein levels in the biofilm. The IC50 of azithromycin
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and cephalexin to P. aeruginosa PA14 with pre-formed biofilm was 27.3 ± 1.4 and 27.7 ± 0.9 µg/mL,
respectively. In the presence of 25 µg/mL azithromycin, in combination with 0.31, 0.63, 1.25 and 2.5 µM
rHPLOE reduced the total protein in the biofilm by 19%, 21%, 39% and 43%, respectively, compared to
the antibiotic-only control (Figure 6).
Table 1. Inhibition percentage (%) of QS-factors in rHPLOE treated P. aeruginosa PA14.
QS-factors
rHPLOE(µM) 0.31 0.63 1.25 2.5
Activities of extracellular proteases 7 ± 1.4 4.8 ± 0.8 15.9 ± 2.2 12.4 ± 1.4
Pyoverdine 12.3 ± 0.2 8.2 ± 0.2 16.7 ± 0.2 21.2 ± 0.2
Pyocyanin 40.8 ± 13.9 56.1 ± 4 45.4 ± 9.2 40.5 ± 24.2Mar. Drugs 2019, 17, x 9 of 19 
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In the presence of 25 µg/mL cephalexin, combination treatment with the same concentrations of
rHPLOE reduced the total protein in biofilms by 33%, 33%, 38% and 50%, respectively, compared to the
antibiotic-only control (Figure 6). This observation suggested that rHPLOE might facilitate antibiotics to
kill P. aeruginosa PA14 by partially interfering with biofilm regulation and thus destroying the structure
of the mature biofilm.
2.9. rHPLOE Inhibited Infection of P. aeruginosa in Mammalian Cells and Zebrafish Embryos
During P. aeruginosa infection, rhamnolipids and pyocyanin are the important virulence factors
causing cytotoxicity. Since rHPLOE inhibited rhamnolipid and pyocyanin production in P. aeruginosa
PA14, we predicted that rHPLOE could also reduce P. aeruginosa PA14 infection inhuman lung cells.
To evaluate this hypothesis, cell death of human lung cell line A549 by P. aeruginosa PA14 infection in
the presence of rHPLOE was examined. As shown in Figure 7, the PA14-infected A549 cell death was
reduced by 14%, 21%, 57% and 73% in the presence of 0.31, 0.63, 1.25 and 2.5 µM rHPLOE, respectively.
Regarding the negative control, 2.5 µM BSA or 2.5 µM rHPLDM did not influence A549 cell death.
These assays clearly demonstrated that the mortality rate of A549 cells killed by P. aeruginosa PA14
decreased due to the presence of rHPLOE. Therefore, rHPLOE attenuated P. aeruginosa PA14 infection
in human lung A549 cells through direct interaction between rHPLOE and rhamnose-containing
bacterial compounds.
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Zebrafish (Danio rerio) has become an important vertebrate animal model for many disease studies
including pathogen infection [37] in recent years. Here fertilized eggs from zebrafish were used as an
animal model to evaluate whether rHPLOE attenuated P. aeruginosa PA14 infection in vivo. Zebrafish
embryos showed normal development in the absence of P. aeruginosa PA14, while the development of
most embryos was significantly delayed or even died at 48 h following infection with P. aeruginosa
PA14 (Figure 8).
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However, when P. aeruginosa PA14 was pre-incubated with 5 µM rHPLOE, 82.2% of embryos
developed normally as compared to control embryos showing a development rate of 90.9%. Zebrafish
embryos treated with 2.5 µM rHPLOE still developed slowly, but almost all of the embryos survived.
These results indicated that rHPLOE could protect zebrafish embryos from P. aeruginosa PA14 infection
at concentrations higher than 2.5 µM.
3. Discussion
To study the carbohydrate components of the biofilm, carbohydrate-binding proteins, such as
plant lectins, have been widely applied. Previously many different neutral carbohydrates including
N-acetyl-d-glucosamine, N-acetyl-d-galactosamine, d-glucose and d-mannose were identified in the
exopolymeric matrix of the biofilm [38]. Lectins with various specificities show an interaction with the
carbohydrate components of biofilms. For example, concanavalin A from Canavalia ensiformis seeds
is specific for d-glucose and d-mannose [39], and lectin from Triticum vulgaris germs is specific for
N-acetyl-d-glucosamine and sialic acid [40]. l-Rhamnose as a unique sugar in bacteria and plants is a
common component of the cell wall and capsule of many pathogenic bacteria including Gram-negative
P. aeruginosa [41], Salmonella typhimurium [42], Vibrio cholera [43,44] as well as Mycobacterium tuberculosis [45].
P. aeruginosa produces at least three distinct exopolysaccharides that contribute to biofilm development
and architecture: Alginate, Pel and Psl [46]. Alginate consists of only uronic acids, Pel is a glucose-rich
polysaccharide and Psl consists of a repeating pentasaccharide containing d-mannose, d-glucose and
l-rhamnose [47]. Psl serves as a primary structural scaffold for biofilm development. In addition, Psl
is involved in early stages of biofilm formation and promoting cell-to-cell interactions [48,49]. Another
rhamnose-containing component in the biofilm was the QS-factor di-rhamnolipid. A mutant strain
(P. aeruginosa PAO1C-rhlAB) that could not produce rhamnolipids lost its swarming activity, which agreed
with our observation in rHPLOE-treated PA14 [50]. rHPLOE bound to both Psl and di-rhamnolipid
through targeting rhamnose moiety and synthetic rhamnobiosides-competitive ELISA showed that
rHPLOE preferred to bind with α(1-3)-rhamnobiose rather than α(1-2)-rhamnobiose. The linkage of the
rhamnose of Psl was reported to be α(1-3) [47] while that of di-rhamnolipid was α(1-2) [51], perhaps
favoring that rHPLOE binding to rhamnose component in biofilm was governed by recognition of unique
structure feature of rhamnosyl moiety. Although rHPLOE binding to Psl still required more abundant
glycan for detail characterization, rHPLOE binding to di-rhamnolipid down-regulated the expression of
di-rhamnolipid and QS-factors of P. aeruginosa and further inhibited biofilm formation.
The most important finding of this study was that the binding of rHPLOE to the P. aeruginosa
PA14 biofilm inhibited biofilm development and disrupted the mature biofilm. Our data clearly
showed that rHPLOE caused these bio-effects by interacting with components in the biofilm including
structural polysaccharides or di-rhamnolipid, largely due to the down-regulation of QS-factors
including di-rhamnolipid, pyocyanin, pyoverdine and extracellular proteases by interrupting the
functions of di-rhamnolipid.
Based on the biofilm dispersion activity of rHPLOE, we proposed that rHPLOE possessed synergistic
effects with antibiotics on P. aeruginosa. Two antibiotics commonly applied for treating P. aeruginosa
infections, azithromycin, a hydrophobic azalide that kills bacteria by decreasing protein production
and cephalexin, a hydrophilic beta-lactam that kills bacteria by inhibiting cell wall synthesis, were used
in this study in combination with rHPLOE. The results showed that rHPLOE significantly improved
the bactericidal activity of both antibiotics, strongly suggesting that rHPLOE was useful as a biofilm
dispersion reagent for deconstructing the biofilm and improving the activities of antibiotics.
Many studies reported that P. aeruginosa infection could be inhibited by down-regulating QS-factors.
Importantly, these anti-QS reagents (allicin, triazolyldihydrofuranone and baicalin hydrate) are effective
against multidrug-resistant P. aeruginosa [33–35]. Studies in the past decade revealed that these anti-QS
reagents also inhibited many human infections caused by biofilm-producing bacteria [52,53]. This fact
is important for fighting human pathogenic bacteria, as biofilms are found to be involved in over
80% of microbial infections in humans [54]. Since rHPLOE could reduce the levels of pyoverdine and
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pyocyanin, we speculate that rHPLOE might also inhibit P. aeruginosa infection. It was found that
rHPLOE significantly reduced the cytotoxicity towards A549 cells and neutralized toxicity (leading to
development retardation or death) of the zebrafish embryo caused by P. aeruginosa PA14.
4. Conclusions
Binding and down-regulation of di-rhamnolipid has not attracted much attention so far. In this
study, we optimized the production of rHPL in E. coli using chaperone co-expression. rHPLOE, a
highly specific rhamnose binding protein, bound to not only bacterial cells and PAMPs [29] but also
extracted cell-free biofilm from P. aeruginosa. In addition, such interaction inhibited biofilm formation
and dispersed mature biofilm through down-regulating secretion of di-rhamnolipid in biofilm and
further down-regulating other QS-factors including extracellular proteases, pyoverdine and pyocyanin.
As a biofilm dispersion reagent, rHPLOE increased the antibiotic activity against P. aeruginosa PA14 with
pre-formed biofilm. Therefore, rHPLOE promised to be an effective anti-biofilm agent for combination
therapy. At cellular and animal levels, rHPLOE inhibited the infection and toxicity of P. aeruginosa
PA14 towards human lung epithelial cells and zebrafish embryos. These results indicated that rHPLOE
served as a novel anti-biofilm agent by targeting rhamnose-containing components in biofilm, which
in turn linked glycan-recognition to novel anti-biofilm strategies against pathogenic bacteria.
5. Materials and Methods
5.1. Bacteria Strains, Growth Medium and Plasmid
Escherichia coli TOP10F’ (Invitrogen, Waltham, MA, USA) was used as a host for vector construction
and DNA manipulation. E. coli BL21(DE3) (Invitrogen, Waltham, MA, USA) was used as a host for
protein expression. Pseudomonas aeruginosa PA14 (serotype O19) was kindly provided by Dr. Hwan-You
Chang (Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan). The vector
pET-23a (+) (Novagen, Burlington, MA, USA) with a T7 promoter was used for recombinant protein
expression in E. coli cells and sequence analysis. Takara’s Chaperone Plasmid Set (#3340, TaKaRa,
Shiga, Japan) was used for chaperone co-expression. All other buffers and reagents were of the highest
commercial purity.
5.2. Expression and Purification of rHPLOE
Chloramphenicol (≥98%, #C0378), ampicillin (96%–102%, #A9393), isopropyl
β-d-1-thiogalactopyranoside (IPTG, ≥99%, #I6758), Tris base (ACS reagent, ≥99.8%, #252859), NaCl
(ACS reagent, ≥99%, #746398), imidazole (≥99%, #I5513), HCl (#320331) and phenylmethylsulfonyl
fluoride (PMSF,≥99%, # 78830) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Luria-Bertani
(LB, #244610) was purchased from BD (Franklin lake, NJ, USA). rHPLOE was the chaperone
co-expressed product of the synthesized sequence (hplOE) and the codon of hplOE was optimized
for E. coli expression. To generate a co-expression clone, pET23a-hplOE was transformed into E. coli
BL21(DE3) competent cells containing pG-KJE8 (#3340, TaKaRa, Shiga, Japan), and transformants were
selected by an LB plate with 20 µg/mL chloramphenicol and 50 µg/mL ampicillin. After induction
with a final concentration of 0.1 mM IPTG at 16 ◦C for 16 h, cells were harvested by centrifugation
(KUBOTA, Osaka, Japan), and the residues were suspended in equilibrium buffer (20 mM Tris-HCl,
200 mM NaCl and 5 mM imidazole, pH 7.4) supplemented with a protease inhibitor (1 mM PMSF) and
disrupted by three passages through a cell homogenizer (Sonicator 3000, Misonix, Farmingdale, NY,
USA) at 15,000 psi. The recombinant proteins were purified using a HisTrap™ HP immobilized metal
ion affinity column (#17524701, GE Healthcare, Little Chalfont, Buckinghamshire, UK) and ÄKTA
start system (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Purified proteins were then
concentrated and buffer-exchanged to the Tris buffer (20 mM Tris-HCl and 200 mM NaCl, pH 7.4) using
a 15 kDa cut off Amicon Ultra centrifugal filter unit (#UFC901096, Millipore, Burlington, MA, USA).
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5.3. Biofilm Formation and Extraction
Bacterial biofilm extraction was as described by Chibaet et al. [55]. P. aeruginosa PA14 grown
on LB plates was inoculated in LB medium and incubated overnight at 37 ◦C with 250 rpm circular
shaking. A portion of the overnight culture was 1000-fold diluted in 10 mL LB medium and incubated
at 37 ◦C to an A600nm of 1. Bacterial cells with biofilm were harvested from incubated solution by
centrifugation at 8000× g for 10 min at 25 ◦C (KUBOTA, Osaka, Japan). The harvested pellet was
re-suspended with 1 mL of 1.5 M NaCl to extract a cell-free biofilm component. The suspensions were
centrifuged at 5000× g for 10 min at 25 ◦C (KUBOTA, Osaka, Japan), and the supernatants containing
the biofilm fraction were collected.
5.4. Polysaccharide Quantification in the Extracted Biofilm
Absolute ethanol (≥99.8%, #32221), phenol (#P1037) and sulfuric acid (95%–98%, #435589) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Polysaccharide in biofilm was measured as
described by Tribedi and Sil [56]. Extracted biofilm solution was mixed with 2.2 volumes of chilled
absolute ethanol, incubated at −20 ◦C for 1 h and centrifuged at 3500× g for 20 min at 4 ◦C (KUBOTA,
Osaka, Japan). The pellet containing exopolysaccharides was dissolved in sterile water and measured
by the phenol-sulfuric acid method. Fifty microliters of re-suspended sample was mixed with 200 µL
phenol, and then, 750 µL sulfuric acid was added. The solution was left standing for 40 min, and
vigorously shaken. After shaking, the A490nm was measured using a spectrophotometer (U3310,
HITACHI, Tokyo, Japan), and the amount of total sugar (excluding amino sugars) was calculated with
a standard curve established using glucose.
5.5. Binding Activity of rHPLOE to Biofilm or Di-Rhamnolipid
Di-rhamnolipid (95%, #R95DD), phosphate buffer saline (PBS, #P3813), Tween-20 (#P1379),
l-rhamnose (≥99%, #R3875), d-glucose (≥99.5%, #G8270), d-galactose (≥99%, #G0750), d-fructose
(≥99%, #F0127), d-mannose (≥99%, #M8574) and sodium alginate (#W201502) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). For competitive enzyme-linked immunosorbent assays (ELISA),
the extracted biofilm or prepared di-rhamnolipid solution (120 µg/mL in ddH2O) was diluted in 10×
the volume of the coating solution (#5150−0014, SeraCare KPL, Milford, MA, USA), and 50 µL of the
mixture was added to each well of the 96-well microplate (#442404, Thermo Fisher, Waltham, MA,
USA) and incubated at 4 ◦C overnight. After blocking with a blocking reagent (#10057177103, Roche,
Basel, Switzerland) at 37 ◦C for 1 h, the plates were washed with PBST (PBS with 0.05% Tween-20) three
times. To the washed wells, 25 µL of 0.2 µM rHPLOE was mixed with 25 µL of two-fold the indicated
concentration of l-rhamnose, d-glucose, d-galactose, d-fructose, d-mannose or sodium alginate and
the mixture was added to the wells, which were maintained at 37 ◦C for 1 h. Fifty microliters of 0.1
µM purified rHPLOE was added in parallel as a positive control, and Tris-buffer (20 mM Tris-HCl
and 200 mM NaCl, pH 7.4) was added in parallel as a negative control. After washing three times
with PBST, the microplates were incubated with monoclonal anti-His-tag (1:5000; #631212, Clontech,
Mountain View, CA, USA) in PBST at 37 ◦C for 1 h. Subsequently, horseradish peroxidase-conjugated
anti-mouse IgG (1:5000; #AB2338512, Jackson ImmunoResearch, West Grove, PA, USA) in PBST was
added to the microplates, and after washing three times with PBST, the plates were incubated at
37 ◦C for 1 h. After being washed three times with PBST, 100 µL of 3,3’,5,5’-tetramethylbenzidine
substrate (#5120-0077, SeraCare KPL, Milford, MA, USA) was added to each well and incubated at
37 ◦C for exactly 15 min. Finally, the reaction was terminated by the addition of 100 µL of 2 N H2SO4.
The A450nm was read using a microplate spectrophotometer (iMark Microplate Absorbance Reader,
Bio-Rad, Hercules, CA, USA). The inhibitory constant (Ki) was analyzed with GraphPad 5.0 software
(GraphPad Software, La Jolla, CA, USA; fitted with a Binding-Competitive/Onesite-Fit Ki).
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5.6. Anti-Biofilm Assay
KH2PO4 (≥99%, #P5655), K2HPO4 (≥99%, #P3768), (NH4)2SO4 (≥99%, #A4418), MgSO4 (≥99.5%,
#M7506), L-arginine (≥98%, #A5006), polymyxin B (meets USP testing specifications, #P0972) and
crystal violet (≥90%, #C0775) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Biofilm
formation was described by O’Toole [57]. Briefly, overnight culture of the P. aeruginosa PA14 in LB
medium was diluted with fresh M63 medium (22 mM KH2PO4, 40 mM K2HPO4, 15 mM (NH4)2SO4,
1 mM MgSO4 and 0.4% l-arginine). A total of 1 × 106 CFU/well bacterial cells were then cultured
with various concentrations of rHPLOE in a final volume of 100 µL M63 medium onto a 96-well clear
round bottom polystyrene microplate (#3788, Thermo Fisher, Waltham, MA, USA) and incubated
at 37 ◦C for 24 h without shaking. A standard antibiotic polymyxin B (50 µg/mL) often used to kill
P. aeruginosa in other studies was applied as a positive control, and M63 only was used as a negative
control. The suspended culture was then discarded, and the plate was washed with ddH2O twice to
remove any remaining suspended cells in the microtiter wells. The biofilm was then stained with
125 µL of 0.1% crystal violet for 15 min, after which the stained biofilm was washed with ddH2O five
times to remove any unbound dye. The crystal violet bound to the biofilm was solubilized with 125 µL
30% (v/v) acetic acid and quantified by measuring the A595nm using the microplate spectrophotometer
(iMark Microplate Absorbance Reader, Bio-Rad, Hercules, CA, USA). For the biofilm dispersion test,
biofilm cultures were grown statically in 80 µL of M63 medium for 24 h, followed by the addition
of 20 µL of the indicated concentration of rHPLOE in M63 medium and incubation for an additional
24 h. The addition of polymyxin B (50 µg/mL) to the culture before biofilm formation was used as a
positive control.
5.7. Swarming Motility Measurement
The swarming motility of P. aeruginosa PA14 was investigated in plates containing swarming
motility media (LB with 0.5% (wt) glucose and 0.6% (wt) agar). Agar was purchased from OXOID
(#LP0011, Basingstoke, Hampshire, UK). An aliquot of 2µL of motility media containing 1× 106 CFU/mL
bacterial cells was inoculated in plates with different concentrations of rHPLOE. Subsequently, spots
were dired for 20 min at room temperature and incubated at 37 ◦C for 48 h. The diameter of the circular
bacterial growth was measured [50].
5.8. Extracellular Rhamnolipid Quantification
Methylene blue (≥82%, #M9140), sodium borate (ACS reagent, ≥99.5%, #S9640) and chloroform
(≥99.5%, #C2432) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Rhamnolipid was
quantified as described by Pinzon et al. [58]. The supernatant of the anti-biofilm test was collected,
and bacterial cells were removed by centrifugation (KUBOTA, Osaka, Japan). The pH of the cell-free
supernatant was first adjusted to 2.3 ± 0.2 using 1 N HCl. Two hundred microliters of acidified sample
was then extracted with the same volume of chloroform five times. One milliliter of the chloroform
extract was carefully removed and mixed with 40 µL of 0.1% methylene blue (freshly prepared and
pH adjusted to 8.6 ± 0.2 with 50 mM borate buffer) and 960 µL of distilled water in a 2 mL tube.
After being vigorously shaken for 4 min, the samples were left to stand for 15 min. The chloroform
phase was transferred into a quartz cuvette and value of A638 nm was measured by spectrophotometer
(U3310, HITACHI, Tokyo, Japan). The values were converted to rhamnolipid concentrations using a
calibration curve established by applying the same procedure to standard rhamnolipid solutions of
different concentrations.
5.9. Azocasein Degradation Assay
The proteolytic activity was determined in the cell-free culture supernatant according to the
method by Kessler et al. [59]. The amount of protease released by P. aeruginosa treated by rHPLOE,
the supernatant of the anti-biofilm test was collected by centrifugation (KUBOTA, Osaka, Japan).
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One hundred and fifty microliters of supernatant were added to 0.3% of 1 mL azocasein (#A2765,
Sigma-Aldrich St. Louis, MO, USA) in 50 mM Tris-HCl (pH 7.5) and incubated at 37 ◦C for 15 min.
The reaction was stopped by the addition of 0.5 mL 10% trichloroacetic acid, and the mixture was
centrifuged at 8000× g for 5 min (KUBOTA, Osaka, Japan) to obtain a clear supernatant. The absorbance
of the clear supernatant was then measured at 400 nm (U3310, HITACHI, Tokyo, Japan) [60].
5.10. Pyoverdine Quantification Assay
P. aeruginosa was incubated with different concentrations of rHPLOE at 37 ◦C for 24 h. Thereafter,
the cultured liquid was centrifuged at 8000× g for 15 min (KUBOTA, Osaka, Japan), and the cell-free
supernatant was used for the pyoverdine measurement. The relative concentrations of pyoverdine
in all of the treated supernatants with respect to the control was measured through a fluorescence
microplate spectrophotometer (Victor2, PerkinElmer, Waltham, MA, USA) at an excitation wavelength
of 405 nm and an emission wavelength of 465 nm [61].
5.11. Pyocyanin Quantification Assay
The pyocyanin quantification assay was performed according to the method described by
Essar et al. [62]. P. aeruginosa was incubated with different concentrations of rHPLOE at 37 ◦C for 24 h,
and the cell-free supernatant was collected by centrifugation (KUBOTA, Osaka, Japan). Five milliliters
of the supernatant were extracted with 3 mL of chloroform and the chloroform layer was re-extracted
with 1 mL of 0.2 N HCl to produce an orange yellow to pink solution, and the chloroform phase was
transferred into a quartz cuvette and value of A520 nm was measured by a spectrophotometer (U3310,
HITACHI, Tokyo, Japan).
5.12. Synergistic Effect of rHPLOE with Antibiotics
The experiment design was according to the method described by Das et al. [63]. P. aeruginosa with
a mature biofilm was treated with rHPLOE in combination with either azithromycin (≥95%, #75199,
Sigma-Aldrich, St. Louis, MO, USA) [63] or cephalexin (≥95%, #C4895, Sigma-Aldrich, St. Louis, MO,
USA) [64]. Solutions of rHPLOE in 0.3125 µM, 0.625 µM, 1.25 µM and 2.5 µM in combination with
different concentrations of antibiotics were directly added to the cultured bacterial liquid with a mature
biofilm and held at 37 ◦C for 24 h. The total protein and amount of biofilm were measured to validate
the synergistic antibacterial effect of rHPLOE and antibiotics.
5.13. Total Protein Concentration Measurement in the Biofilm
Concentration of the extractable protein was determined as a measure of the P. aeruginosa
biofilm population density. The microbial population density in the biofilm is assumed to be directly
proportional to the extractable protein concentration [56]. After incubation, planktonic P. aeruginosa
cells were removed, and adhered cells remained in the biofilm were gently washed with sterile PBS
and boiled for 30 min in 5 mL of 0.5 N NaOH (ACS reagent, ≥97%, #221465, Sigma-Aldrich, St. Louis,
MO, USA) to extract the protein. After that, the suspension was centrifuged at 8000× g for 5 min
(KUBOTA, Osaka, Japan), and the resulting clear supernatant was collected. The supernatant protein
concentration was then measured by the bicinchoninic acid (BCA) protein assay kit (#23225, Thermo
Fisher, Waltham, MA, USA).
5.14. Anti-A549 Infection Assay
The Roswell Park Memorial Institute (RPMI)-1640 medium (#10-040 CMS) and Antibiotics–
Antimycotic solution (PSA, #30-004-CIS) was purchased from Corning (Corning, NY, USA).
Characterized fetal bovine serum (FBS, #SH30071) was purchased from HyClone Laboratory (Logan,
UT, USA). The A549 infection model was modified from method described by Chi [65]. A549 cells
(ATCC® number: CCL-185™, BCRC, Hsinchu, Taiwan), adenocarcinomic human lung cells, were
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seeded in 96-well tissue culture plates at 2× 104 containing 100 µL of RPMI-1640 medium supplemented
with 10% (v/v) fetal FBS and 1% (v/v) PSA and allowed to grow at 37 ◦C for 16 to 18 h. Culture
supernatants were removed, the monolayer was washed once with PBS buffer, and then 50 µL of
serum-free RPMI-1640 containing two times the indicated concentration of rHPLOE was added to cells
and incubated for 30 min, followed by inoculation with P. aeruginosa PA14. RPMI-1640 with 5 µM BSA
or rHPLDM was used as negative controls. For inoculation, the fresh bacterial cells cultured in LB
broth were washed with PBS, re-suspended and diluted in RPMI-1640 medium to a concentration of
1 × 108 CFU/mL. Thereafter, 50 µL of the bacterial dilution was applied to the rHPLOE-treated A549
cells at a multiplicity of infection (MOI) of 50 (i.e., 1 × 106 CFU/50 µL/well). The blank group was
A549 cells treated by 2.5 µM rHPLOE without bacterial infection. After infection for 16 h at 37 ◦C, the
A549 cell viability was determined by the AlamarBlue cell viability assay (BUF012B, Bio-Rad, Hercules,
CA, USA). It should be noted that 50 µg/mL polymyxin B should be added to alamarBlue reagent to
prevent a survival signal from residual bacteria. The level of viability, expressed as a percentage, was
calculated as follows: % viability = [OD of assay cells/OD of control cells] × 100.
5.15. Anti-Zebrafish Infection Assay
Zebrafish embryos were purchased from Gendanio Biotech Inc. (New Taipei City, Taiwan).
Healthy, transparent and regular embryos were selected and aliquoted into 96-well plates with four
embryos per well, followed by incubation at 28 ◦C in 100 µL embryo water. Thereafter, 100 µL of
P. aeruginosa (1 × 108 CFU/mL) pre-incubated with 5 mM rHPLOE for 1 h was added to the embryos
at 24 h post-fertilization (hpf). The zebrafish embryos were further incubated at 28 ◦C, and the
development of each embryo in 24 h and 48 h was observed using an inverted microscope (TS100,
NIKON, Tokyo, Japan) equipped with a digital camera. The number of larva at 48 h in each group was
counted, and the rate of successful development was calculated. All zebrafish related experiments
were conducted in accordance with the ethical guidelines of Council of Agriculture, Executive Yuan
and Ministry of Science and Technology.
5.16. Statistical Analyses
All statistical analyses were carried out using GraphPad Prism version 5.01 for Windows (GraphPad
Software, La Jolla, CA, USA). Each value was the average of three measurements, where the presented
data is the mean ± SD. All means were compared by one-way ANOVA.
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